Rosiglitazone plus exenatide shows lower percentage of MI….
According to the FDA’s Adverse Event Reporting System (AERS), Iyengar and colleagues found that a combination of rosiglitazone plus exenatide showed a lower percentage of myocardial infarction compared with rosiglitazone monotherapy (2% vs 34%).
It is believed the plasminogen activator inhibitor-1 (PAI-1) is involved in the interaction between rosiglitazone and exenatide (p=0.016). PARI-1 is a predictor of clot risk. He believe since rosiglitazone has cardiovascular adverse effects that increases the risk of MI and stroke, then the clotting dynamics in the body has to be altered when combined with exenatide.
An experiment was done on mice where treatment of rosiglitazone only resulted in a 74% increase in PAI-1 levels. When the drug was in combination with exenatide, the PAI-1 levels were similar. They concluded that the exenatide prevented the increased in PAI-1 as seen in the monotherapy of rosiglitazone.
- Rosiglitazone has potential cardiovascular adverse effects.
- PAI-1 plays a role between exenatide and rosiglitazone.
- GLP-1 may interfere with CVD risk associated with rosiglitazone
Science Translational Medicine 2013